6.010USD+6.010盘后交易 08/03, 20:00 (美东)
关键数据
6.010今开
6.010最高
608.88K成交量
亏损市盈率 TTM
23.63市盈率动
--股息TTM
0.92%换手率
6.010昨收
5.720最低
2.41M成交额
亏损市盈率静
-13.36市净率
0.00%股息率 TTM
-20.01%ROA
10.62052周最高
0.98量比
-50.42M净利润
65.84M总股本
-0.6682每股收益TTM
1.34Beta
-18729.61%ROE
3.86052周最低
4.82%振幅
64.27%毛利率
384.59M总市值
-4.21回报/风险
3.33%风险率
操作建议
Evolus Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名34/155位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价14.67。中期看,股价处于平稳状态。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Evolus Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Evolus Inc简介
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
公司代码EOLS
公司Evolus Inc
CEOMoatazedi (David)
网址https://www.evolus.com/
公司股东
常见问题
Evolus Inc(EOLS)的当前股价是多少?
Evolus Inc(EOLS)的当前股价是 5.84。
Evolus Inc股票的52周最高点是10.62。
Evolus Inc股票的52周最低点是3.86。
现在Evolus Inc(EOLS)的股票是买入、持有还是卖出?
根据分析师评级,Evolus Inc(EOLS)的总体评级为买入,目标价格为14.67。
Evolus Inc(EOLS)股票的每股收益(EPS TTM)是多少
Evolus Inc(EOLS)股票的每股收益(EPS TTM)是-0.80。